Solvias, a company in contract research, development and manufacturing for the pharmaceutical, biotech, material science and cosmetic industries, completed the acquisition of Cergentis, a trusted genomics-focused biotechnology company. Financial terms were not disclosed. “We are relentlessly focused on ensuring the safety of new therapies in development. Cergentis is a cornerstone acquisition that expands our solutions supporting complex and emerging therapies. We will continue to pursue strategic acquisitions that add specialized capabilities to our offering and advance our goal of being a forerunner in our industry,” Archie Cullen, Solvias CEO.